Exec VP Hans Mueller to chief operating officer; University of Texas Medical School (Houston) Prof S. J. Enna to senior VP and scientific director.
You may also be interested in...
The device can conduct laparoscopic hysterectomies, giving surgeons more mobility while leaving less scarring.
Nulibry obtains FDA approval weeks ahead of its action date. Although small patient base offers modest revenue opportunity, approval enables BridgeBio to get commercial operations underway.
Since raising $135m in 2017 to address rare, monogenic diseases, BridgeBio has launched or purchased 17 companies and built a pipeline of 30-plus candidates. Scrip checked in as the company nears commercialization.